In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

La Jolla Pharmaceutical Company. Trade Record

NASDAQ:LJPC La Jolla Pharmaceutical Company stock gains 12.79% Exit Mar 20, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart LJPC Mar 4, 2019, priceSeries
About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. The company is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
88.66
Entry Date
Mar 4, 2019
Entry Price
6.33
Sell Date
Mar 20, 2019
Sell Price
7.14
Net Gain
12.79%
Hold Time
12 Trading Days